Toobit Launches March Spot Challenge with Deposit and Trading Prizes

GEORGE TOWN, Cayman Islands, March 05, 2026 (GLOBE NEWSWIRE) — Toobit, the award-winning global cryptocurrency exchange, today launches its March spot challenge, featuring a 150,000 USDT prize pool in token airdrops and trading vouchers. By completing on-chain deposits and meeting trading volume milestones, participants can unlock mystery boxes. This straightforward reward structure ensures the challenge […]

Toobit Launches March Spot Challenge with Deposit and Trading Prizes

Toobit Launches March Spot Challenge with Deposit and Trading Prizes GlobeNewswire March 05, 2026 GEORGE TOWN, Cayman Islands, March 05, 2026 (GLOBE NEWSWIRE) — Toobit, the award-winning global cryptocurrency exchange, today launches its March spot challenge, featuring a 150,000 USDT prize pool in token airdrops and trading vouchers. By completing on-chain deposits and meeting trading

Snowflake Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – SNOW

The DJS Law Group reminds investors of a class action lawsuit against Snowflake Inc. (“Snowflake ” or “the Company”) (NYSE: SNOW ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of SNOW during the

TORM plc – Notice of and Complete Proposals for the Annual General Meeting 2026

Reference is made to TORM plc's (NASDAQ: TRMD) (NASDAQ: TRMD A) company announcement dated 5 March 2026. Please find enclosed formal notice of, and full details of the business to be proposed at, the Annual General Meeting (“AGM”) of TORM plc to be held at noon (London time) on Wednesday, 15 April 2026. Contacts Christopher

Boliden publishes Annual and Sustainability Report 2025

Boliden's Annual and Sustainability Report 2025 is now available at www.boliden.com. It highlights how Boliden creates value and covers topics such as strategy, operations, sustainability and financial performance. The report's overhead theme is A solid foundation for today and beyond. A printed version, available in April, can only be ordered from Order Annual Report on

Press Release: Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director

(Paris:SAN), Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent director Paris, March 5, 2026. The Board of Directors of Sanofi has decided to propose, at the next Annual General Meeting of shareholders scheduled for April 29, 2026, the appointment of Christel Heydemann as an independent director, as well as the

Press Release: Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director

Press Release: Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent director GlobeNewswire March 05, 2026 Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent director Paris, March 5, 2026. The Board of Directors of Sanofi has decided to propose, at the next Annual General Meeting of

Henan intensifies efforts for higher-level opening-up

A news report from chinadaily.com.cn: Henan province is stepping up efforts to become a higher-level inland opening-up hub by strengthening trade and logistics links with domestic and international markets. “We are working to continuously expand opening-up both internally and externally, taking integration into and the service of the national unified market as the driving force,

Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals

(TSE:4565.T), Tokyo, Japan and Cambridge, UK, 5 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment

Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals

Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals GlobeNewswire March 05, 2026 Tokyo, Japan and Cambridge, UK, 5 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development milestone associated with its investigational, orally administered, highly potent and

Scroll to Top